318 related articles for article (PubMed ID: 27196778)
21. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma.
Madore J; Strbenac D; Vilain R; Menzies AM; Yang JY; Thompson JF; Long GV; Mann GJ; Scolyer RA; Wilmott JS
Clin Cancer Res; 2016 Aug; 22(15):3915-23. PubMed ID: 26960397
[TBL] [Abstract][Full Text] [Related]
23. IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages.
Mohamed HT; El-Husseiny N; El-Ghonaimy EA; Ibrahim SA; Bazzi ZA; Cavallo-Medved D; Boffa MB; El-Shinawi M; Mohamed MM
Curr Probl Cancer; 2018; 42(2):215-230. PubMed ID: 29459177
[TBL] [Abstract][Full Text] [Related]
24. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.
Sweis RF; Spranger S; Bao R; Paner GP; Stadler WM; Steinberg G; Gajewski TF
Cancer Immunol Res; 2016 Jul; 4(7):563-8. PubMed ID: 27197067
[TBL] [Abstract][Full Text] [Related]
25. Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.
Nowicki TS; Akiyama R; Huang RR; Shintaku IP; Wang X; Tumeh PC; Singh A; Chmielowski B; Denny C; Federman N; Ribas A
Cancer Immunol Res; 2017 Feb; 5(2):118-126. PubMed ID: 28039162
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H
Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663
[No Abstract] [Full Text] [Related]
27. Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers.
Forrest SJ; Al-Ibraheemi A; Doan D; Ward A; Clinton CM; Putra J; Pinches RS; Kadoch C; Chi SN; DuBois SG; Leavey PJ; LeBoeuf NR; Mullen E; Collins N; Church AJ; Janeway KA
Clin Cancer Res; 2020 Jun; 26(12):2882-2890. PubMed ID: 32122923
[TBL] [Abstract][Full Text] [Related]
28. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
[TBL] [Abstract][Full Text] [Related]
29. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
30. Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.
Kraya AA; Maxwell KN; Wubbenhorst B; Wenz BM; Pluta J; Rech AJ; Dorfman LM; Lunceford N; Barrett A; Mitra N; Morrissette JJD; Feldman M; Nayak A; Domchek SM; Vonderheide RH; Nathanson KL
Clin Cancer Res; 2019 Jul; 25(14):4363-4374. PubMed ID: 30914433
[TBL] [Abstract][Full Text] [Related]
31. Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers.
Li X; Kumar S; Harmanci A; Li S; Kitchen RR; Zhang Y; Wali VB; Reddy SM; Woodward WA; Reuben JM; Rozowsky J; Hatzis C; Ueno NT; Krishnamurthy S; Pusztai L; Gerstein M
Genome Med; 2021 Apr; 13(1):70. PubMed ID: 33902690
[TBL] [Abstract][Full Text] [Related]
32. Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells.
Ohue Y; Kurose K; Nozawa R; Isobe M; Nishio Y; Tanaka T; Doki Y; Hori T; Fukuoka J; Oka M; Nakayama E
Cancer Immunol Res; 2016 Dec; 4(12):1049-1060. PubMed ID: 27799141
[TBL] [Abstract][Full Text] [Related]
33. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Wen WX; Leong CO
PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
[TBL] [Abstract][Full Text] [Related]
34. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
[TBL] [Abstract][Full Text] [Related]
35. Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
Parkes EE; Walker SM; Taggart LE; McCabe N; Knight LA; Wilkinson R; McCloskey KD; Buckley NE; Savage KI; Salto-Tellez M; McQuaid S; Harte MT; Mullan PB; Harkin DP; Kennedy RD
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707838
[TBL] [Abstract][Full Text] [Related]
36. A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer.
Mayoh C; Gifford AJ; Terry R; Lau LMS; Wong M; Rao P; Shai-Hee T; Saletta F; Khuong-Quang DA; Qin V; Mateos MK; Meyran D; Miller KE; Yuksel A; Mould EVA; Bowen-James R; Govender D; Senapati A; Zhukova N; Omer N; Dholaria H; Alvaro F; Tapp H; Diamond Y; Pozza LD; Moore AS; Nicholls W; Gottardo NG; McCowage G; Hansford JR; Khaw SL; Wood PJ; Catchpoole D; Cottrell CE; Mardis ER; Marshall GM; Tyrrell V; Haber M; Ziegler DS; Vittorio O; Trapani JA; Cowley MJ; Neeson PJ; Ekert PG
Genome Med; 2023 Apr; 15(1):20. PubMed ID: 37013636
[TBL] [Abstract][Full Text] [Related]
37. An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer.
McLemore LE; Janakiram M; Albanese J; Shapiro N; Lo Y; Zang X; Fineberg S
Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):611-619. PubMed ID: 28422766
[TBL] [Abstract][Full Text] [Related]
38. Anti-tumor effects of Ganoderma lucidum (reishi) in inflammatory breast cancer in in vivo and in vitro models.
Suarez-Arroyo IJ; Rosario-Acevedo R; Aguilar-Perez A; Clemente PL; Cubano LA; Serrano J; Schneider RJ; Martínez-Montemayor MM
PLoS One; 2013; 8(2):e57431. PubMed ID: 23468988
[TBL] [Abstract][Full Text] [Related]
39. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
Noh BJ; Kwak JY; Eom DW
BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
[TBL] [Abstract][Full Text] [Related]
40. Whole transcriptome analysis of gestational trophoblastic neoplasms reveals altered PI3K signaling pathway in epithelioid trophoblastic tumor.
Cho EJ; Chun SM; Park H; Sung CO; Kim KR
Gynecol Oncol; 2020 Apr; 157(1):151-160. PubMed ID: 31954539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
